PTIX (Protagenic Therapeutics) 3-Year Book Growth Rate: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PTIX Protagenic Therapeutics Inc PTIX
26 GF Score
Price $0.83
! 2 Warning Signs
View Full Analysis

What is Protagenic Therapeutics 3-Year Book Growth Rate?

Protagenic Therapeutics PTIX 26 3-Year Book Growth Rate is 0.00% as of Dec. 2025. GuruFocus rates PTIX with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,123 Biotechnology companies, Protagenic Therapeutics ranks worse than 89047.11% on this metric.

Protagenic Therapeutics's Book Value per Share for the quarter that ended in Dec. 2025 was $-1.24.

During the past 12 months, Protagenic Therapeutics's average Book Value per Share Growth Rate was -163.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Protagenic Therapeutics  (OTCPK:PTIX) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Protagenic Therapeutics 3-Year Book Growth Rate Related Terms

PTIX vs SCNI, DCOY, BBLG: 3-Year Book Growth Rate Comparison

For the Biotechnology subindustry, Protagenic Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Protagenic Therapeutics 3-Year Book Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Protagenic Therapeutics's 3-Year Book Growth Rate falls into.


PTIX
26GF Score
Protagenic Therapeutics Inc PTIX
3-Year Book Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protagenic Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

What does a 3-Year Book Growth Rate of 0.00% mean?
Protagenic Therapeutics (PTIX) has a 3-Year Book Growth Rate of 0.00% as of Dec. 2025. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Protagenic Therapeutics and its competitors. According to the industry distribution chart, Protagenic Therapeutics ranks #999999 out of 1123 companies in the Biotechnology industry.
Is Protagenic Therapeutics' 3-Year Book Growth Rate too high?
Protagenic Therapeutics' current 3-Year Book Growth Rate is 0.00%. Based on the distribution chart, Protagenic Therapeutics ranks #999999 out of 1123 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Protagenic Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Protagenic Therapeutics' 3-Year Book Growth Rate compare to SCNI and DCOY?
According to the Biotechnology industry distribution chart, Protagenic Therapeutics ranks #999999 out of 1123 companies for 3-Year Book Growth Rate. This places Protagenic Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Protagenic Therapeutics and its competitors. Protagenic Therapeutics's current 3-Year Book Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagenic Therapeutics stock overvalued right now?
Protagenic Therapeutics (PTIX) has a current 3-Year Book Growth Rate of 0.00%. The current 3-Year Book Growth Rate is 0.00%. Protagenic Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Protagenic Therapeutics (PTIX), the current 3-Year Book Growth Rate is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Protagenic Therapeutics Business Description

Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
26GF Score

Get the complete analysis for PTIX

3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.83
Price